Teva Pharmaceuticals Files 8-K on Security Holder Vote Matters
Ticker: TEVJF · Form: 8-K · Filed: Jun 5, 2025 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Teva's voting on key issues, shareholders get a say.
AI Summary
On June 5, 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD filed an 8-K report indicating a submission of matters to a vote of security holders. The filing details are for the period ending June 5, 2025, with the company's principal executive offices located at 124 Dvora Hanevi'a Street, Tel Aviv, Israel.
Why It Matters
This filing signals that Teva Pharmaceutical Industries Ltd is engaging its security holders on important corporate decisions, which could impact future strategic direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial risks or significant operational changes.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- June 5, 2025 (date) — Date of Report
- 124 Dvora Hanevi'a Street, Tel Aviv, Israel (location) — Principal Executive Offices
FAQ
What specific matters are being submitted to a vote of security holders?
The filing indicates a submission of matters to a vote of security holders, but the specific details of these matters are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 5, 2025.
What is the principal executive office address for TEVA PHARMACEUTICAL INDUSTRIES LTD?
The principal executive office address is 124 Dvora Hanevi'a Street, Tel Aviv 6944020, Israel.
What is the Commission File Number for TEVA PHARMACEUTICAL INDUSTRIES LTD?
The Commission File Number for TEVA PHARMACEUTICAL INDUSTRIES LTD is 001-16174.
Under which section of the Securities Exchange Act is this Current Report filed?
This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF).